依那普利联合美托洛尔治疗充血性心力衰竭58例

Efficacy of combination therapy with enalapril and metoprolol on 58 patients with congestive heart failure

目的观察依那普利联合美托洛尔治疗慢性充血性心力衰竭的临床疗效及安全性。方法选择我院近年来收治的慢性充血性心力衰竭患者58例，随机分为观察组30例和对照组28例，对照组给予常规强心、利尿、扩血管等基础治疗，观察组在常规治疗基础上加用依那普利10mg，每日2次，美托洛尔12．5—25．0mg，每日2次，疗程10周，观察两组的治疗效果及不良反应。结果观察组总有效率83．3％，对照组总有效率为67．9％，两组比较差异有统计学意义，P〈0．05，两组均未出现严重不良反应。结论依那普利联合美托洛尔治疗慢性心力衰竭疗效满意，且用药安全，可明显改善患者预后。

Objective To evaluate the safety and clinical efficacy of combination therapy with enalapril and metoprolol for congestive heart failure （CHF）. Methods Fifty - eight patients with CHF were divided randomly into control group （ n= 28） and combined treatment group （ n =30）. The conventional CHF therapy was given in control group. In combined treatment group ,combination therapy with enalapril 10 mg and metoprolol 12.5 -25.0 mg twice a day plus conventional therapy same as in control group was performed for 10 weeks. The therapeutic effect and adverse effects were observed. Results Total efficacy in control group was 67.9% （ 19 patients） versus 83.3 % （25 patients） in combined treatment group. The comparison holds statistical significance. Conclusion The efficacy and safety of combination therapy with enalapril and lnetoprolol for congestive heart failure is convincing, and the prognosis is improved.